retatrutide safety trial Efficacy and of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 ⚠️ BEWARE OF RETATRUTIDE SOLD

One recent analysis of six years of medical records from the Department of Veterans Affairs, which reviewed the records of 2 million patients with diabetes, found that those taking a GLP-1 agonist medication had a reduced risk of developing dementia, including Alzheimers, as well as psychiatric and substance use disorders, though it also found an increased risk of gastrointestinal disorders, kidney stones, and pancreatitis

Embryonic origin of amphibian taste buds

GLP-1 analogs were subcutaneously injected once daily for 21 days

Our product contains only the Stabilized R-Lipoic Acid 600mg without the ineffective S- form

McLean BA, Wong CK, Kaur KD, et al

Do not use within 3 hours of bedtime as it may interfere with sleep